Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer-Reference-Cited by-同舟云学术

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Published:2021-12-01 Issue:12 Volume:7 Page:1856
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Nebhan Caroline A.¹,Cortellini Alessio²³,Ma Weijie⁴⁵,Ganta Teja⁶,Song Haocan⁷,Ye Fei⁷,Irlmeier Rebecca⁷,Debnath Neha⁶,Saeed Anwaar⁸,Radford Maluki⁸,Alahmadi Asrar⁹¹⁰,Diamond Akiva⁹¹¹,Hoimes Christopher⁹¹²,Ramaiya Nikhil⁹,Presley Carolyn J.¹³,Owen Dwight H.¹³,Abou Alaiwi Sarah¹⁴,Nassar Amin¹⁴,Ricciuti Biagio¹⁵,Lamberti Giuseppe¹⁶,Bersanelli Melissa¹⁷,Casartelli Chiara¹⁷,Buti Sebastiano¹⁷,Marchetti Paolo¹⁸,Giusti Raffaele¹⁸,Filetti Marco¹⁸,Vanella Vito¹⁹,Mallardo Domenico¹⁹,Macherla Shravanti²⁰,Sussman Tamara A.²¹,Botticelli Andrea²²,Galetta Domenico²³,Catino Annamaria²³,Pizzutilo Pamela²³,Genova Carlo²⁴²⁵,Dal Bello Maria Giovanna²⁴,Kalofonou Foteini³,Daniels Ella³,Ascierto Paolo A.¹⁹,Pinato David J.³²⁶,Choueiri Toni K.¹⁴,Johnson Douglas B.¹,Marron Thomas U.⁶,Wang Yinghong⁴,Naqash Abdul Rafeh²⁰²⁷²⁸

Affiliation:

1. Vanderbilt University Medical Center, Nashville, Tennessee

2. Department of Biotechnology and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

3. Department of Surgery and Cancer, Imperial College London, London, United Kingdom

4. The University of Texas MD Anderson Cancer Center, Houston

5. Zhongnan Hospital of Wuhan University, Wuhan, China

6. Icahn School of Medicine at Mount Sinai, New York, New York

7. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee

8. University of Kansas Cancer Center, Kansas City

9. Case Western Reserve University, Division of Hematology & Oncology, Cleveland, Ohio

10. Ohio State University, The James Comprehensive Cancer Center, Columbus

11. Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas

12. Duke Cancer Institute, Duke University, Durham, North Carolina

13. The Ohio State University Comprehensive Cancer Center, Columbus

14. Dana-Farber Cancer Center, Boston, Massachusetts

15. Department of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy

16. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

17. Medical Oncology Unit, University Hospital of Parma and Medicine and Surgery Department, University of Parma, Parma, Italy

18. Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant’Andrea, Rome, Italy

19. Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

20. East Carolina University Brody School of Medicine, Division of Hematology & Oncology, Greenville, North Carolina

21. Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio

22. Policlinico Umberto I, Clinical and Molecular Department, Sapienza University of Rome, Rome, Italy

23. IRCCS Istituto Tumori Giovanni Paolo II, Medical Thoracic Oncology Unit, Bari, Italy

24. UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy

25. Dipartimento di Medicina Interna e Specialità Mediche, Università degli Studi di Genova, Genova, Italy

26. Department of Translational Medicine, University of Piemonte Orientale “A. Avogadro”, Novara, Italy

27. Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland

28. Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2785698/jamaoncology_nebhan_2021_br_210015_1639155166.7513.pdf

Reference13 articles.

1. Participation of the elderly population in clinical trials: barriers and solutions.;Denson;Cancer Control,2014

2. FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. Food and Drug Administration.;Harpreet Singh;Journal of Clinical Oncology,2017

3. Barriers to clinical trial enrollment of older adults with cancer: a qualitative study of the perceptions of community and academic oncologists.;Sedrak;J Geriatr Oncol,2020

4. Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.;Patrinely;Eur J Cancer,2020

5. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis.;Wang;JAMA Oncol,2018

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes;Frontiers in Immunology;2024-09-10

2. Comparative analysis of adverse event risks in breast cancer patients receiving pembrolizumab combined with paclitaxel versus paclitaxel monotherapy: insights from the FAERS database;Frontiers in Pharmacology;2024-08-21

3. Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer;Scientific Reports;2024-08-16

4. Predictors of survival in immunotherapy‐based treatments in advanced melanoma: a meta‐analysis;International Journal of Dermatology;2024-08-04

5. Treatment of elderly patients with head and neck cancer in an aging society: Focus on geriatric assessment and surgical treatment;Auris Nasus Larynx;2024-08